Access Dermatology

Breaking News

• Breaking News List »
• breaking_news_2008 »
• 09 »

Infliximab improves health-related quality of life in psoriasis patients with comorbidities

A multicenter, double-blind, placebo-controlled trial in 835 patients with moderate to severe plaque psoriasis assessed the effects of infliximab (3 or 5 mg/kg i.v.) or placebo on disease severity and health-related quality of life (HRQoL). The patients had a variety of comorbidities, the most common being psoriatic arthritis (PsA), hypertension, hyperlipidemia, depression, sinusitis, chronic obstructive pulmonary disease/asthma. Patients received infliximab at weeks 0, 2 and 6. Infliximab patients were rerandomized at week 14 to receive the same treatment every 8 weeks or as needed through week 46. Placebo patients were switched to infliximab at week 16. Disease severity was assessed by Psoriasis Area and Severity Index (PASI) and HRQoL by the Dermatology ...